Mounjaro (Tirzepatide 2.5/5mg) Aesthetic Weight Loss
Dual GLP-1/GIP receptor agonist for natural appetite suppression & aesthetic weight management
About This Treatment
Mounjaro (tirzepatide) by Eli Lilly is the world's first dual GLP-1/GIP receptor agonist. Simultaneously activating two incretin pathways achieves natural appetite suppression, enhanced satiety, and improved glucose metabolism. SURMOUNT trials showed up to 20.9% weight loss, surpassing single-agent GLP-1 drugs. Aesthetic clinics start with low doses (2.5mg, 5mg) for cosmetic weight management. Note: rapid weight loss may cause "Ozempic face" (facial volume loss) requiring complementary treatments (fillers, RF tightening).
Mechanism of Action
Tirzepatide is a dual agonist binding both GIP and GLP-1 receptors. GLP-1 pathway delays gastric emptying and acts on hypothalamic satiety centers to suppress appetite. GIP pathway improves adipose tissue metabolism and insulin sensitivity. Synergistic dual pathway effect produces weight loss superior to GLP-1 monotherapy. Administered as weekly subcutaneous injection.
Indications
Expected Results
Average 19.5% weight loss with 10mg, 20.9% with 15mg (vs 3.1% placebo). Significant weight loss even at low 2.5-5mg doses.
Clinical Evidence
Risks & Side Effects
GI symptoms (nausea, vomiting, diarrhea, constipation) most common (5-30%). Mitigated by gradual dose escalation. Rare pancreatitis/cholecystitis. Caution for facial volume loss ("Ozempic face") with rapid weight loss. Contraindicated in pregnancy/lactation.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition